A combination of AbbVie’s venetoclax and Roche/Genentech’s rituximab significantly improved progression-free survival (PFS) in patients with chronic lymphocytic leukaemia (CLL), shows data published by the New England Journal of Medicine
Original Article: NEJM publishes venetoclax/rituximab data
NEXT ARTICLE